These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 8564262

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antagonistic actions of renal dopamine and 5-hydroxytryptamine: increase in Na+, K(+)-ATPase activity in renal proximal tubules via activation of 5-HT1A receptors.
    Soares-da-Silva P, Pinto-do-O PC, Bertorello AM.
    Br J Pharmacol; 1996 Mar; 117(6):1199-203. PubMed ID: 8882616
    [Abstract] [Full Text] [Related]

  • 27. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain.
    Casanovas JM, Lésourd M, Artigas F.
    Br J Pharmacol; 1997 Oct; 122(4):733-41. PubMed ID: 9375971
    [Abstract] [Full Text] [Related]

  • 28. Diabetes-induced changes in 5-hydroxytryptamine modulation of vagally-induced bradycardia in rat heart.
    García M, Morán A, Martín ML, Ortizde Urbina AV, San Román L.
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1199-206. PubMed ID: 17880377
    [Abstract] [Full Text] [Related]

  • 29. Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist.
    Defraiteur C, Plenevaux A, Scuvée-Moreau J, Rouchet N, Goblet D, Luxen A, Seutin V.
    Br J Pharmacol; 2007 Nov; 152(6):952-8. PubMed ID: 17704821
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist.
    Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozlan H, Hamon M, Dourish CT.
    Behav Brain Res; 1996 Nov; 73(1-2):337-53. PubMed ID: 8788530
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
    Dawson LA, Nguyen HQ, Smith DL, Schechter LE.
    J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
    [Abstract] [Full Text] [Related]

  • 37. BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex.
    Borsini F, Ceci A, Bietti G, Donetti A.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Sep; 352(3):283-90. PubMed ID: 8584043
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. 5-HT1A receptor antagonists and lordosis behavior.
    Uphouse L, Andrade M, Caldarola-Pastuszka M, Jackson A.
    Neuropharmacology; 1996 Apr; 35(4):489-95. PubMed ID: 8793912
    [Abstract] [Full Text] [Related]

  • 40. 5-HT(1A) agonist potential of pindolol: electrophysiologic studies in the dorsal raphe nucleus and hippocampus.
    Sprouse J, Braselton J, Reynolds L.
    Biol Psychiatry; 2000 Jun 15; 47(12):1050-5. PubMed ID: 10862804
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.